Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade

LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation

(2018) Winson S. Ho et al.   CANCER LETTERS

Cancer Immunology and Immunotherapy

(2016) AMMAR SUKARI et al.   ANTICANCER RESEARCH

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

(2016) Vincent Chung et al.   CLINICAL CANCER RESEARCH

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

(2016) Peter J.R. Ebert et al.   IMMUNITY

Ionic immune suppression within the tumour microenvironment limits T cell effector function

(2016) Robert Eil et al.   NATURE

PP2A's restraint of mTOR is critical for Treg cell activity

(2016) Greg M Delgoffe   NATURE IMMUNOLOGY

Phosphatase PP2A is requisite for the function of regulatory T cells

(2016) Sokratis A Apostolidis et al.   NATURE IMMUNOLOGY

Rescue of GABAB and GIRK function in the lateral habenula by protein phosphatase 2A inhibition ameliorates depression-like phenotypes in mice

(2016) Salvatore Lecca et al.   NATURE MEDICINE

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

(2015) Christopher S Hong et al.   CANCER BIOLOGY & THERAPY

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma

(2015) I. K. Gordon et al.   MOLECULAR CANCER THERAPEUTICS

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

(2015) Idit Sagiv-Barfi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PP2A: The Wolf in Sheep’s Clothing?

(2015) Maeve Kiely et al.   Cancers

Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis

(2014) Xueli Bai et al.   CANCER LETTERS

mTOR signaling, Tregs and immune modulation

(2014) Nicole M Chapman et al.   Immunotherapy

Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

(2014) X.-L. Bai et al.   MOLECULAR CANCER THERAPEUTICS

The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity

(2014) K.-E. Chang et al.   MOLECULAR CANCER THERAPEUTICS

In vivo discovery of immunotherapy targets in the tumour microenvironment

(2014) Penghui Zhou et al.   NATURE

Live screening of immunotherapy targets

(2014) Katie Kingwell   NATURE REVIEWS DRUG DISCOVERY

T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy

(2014) I. Melero et al.   Cancer Discovery

Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

(2013) D. Wei et al.   CLINICAL CANCER RESEARCH

Viewing serine/threonine protein phosphatases through the eyes of drug designers

(2013) Mengmeng Zhang et al.   FEBS Journal

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells

(2012) V. Janssens et al.   CURRENT MOLECULAR MEDICINE

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2

(2011) Greg M Delgoffe et al.   NATURE IMMUNOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms

(2009) Jie Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+cells

(2008) Sokol Haxhinasto et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail)

(2008) Veerle Janssens et al.   TRENDS IN BIOCHEMICAL SCIENCES